Trial Profile
A Phase I Study of SU5416 [semaxanib] in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2009
Price :
$35
*
At a glance
- Drugs Semaxanib (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacokinetics
- 20 Oct 2009 Planned end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 20 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.